

ok
Ziska

#10

PATENT
Atty Dkt 4364-0002.22

I hereby certify that this correspondence is being hand-carried to the Commissioner of Patents and Trademarks,
Washington, D.C. 20231 on 25 May 1994.

25 May 1994
Date

Regina Buckhouse
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

R. Kucherlapati, et al.

Serial No.: 08/031,801

Group Art Unit: 1802⁴

Filing Date: 15 March 1993

Examiner: S. Ziska

Title: GENERATION OF XENOGENEIC ANTIBODIES

COMMUNICATION AND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

RECEIVED
MAY 25 1994

The Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

GROUP 180

Dear Sir:

Attention of the Office is called to the enclosed PCT application WO 92/03918 assigned to GenPharm International, Inc. and cited on the attached PTO Form 1449 to ensure consideration by the Office. This published application is not a reference with respect to the claims pending herein as its publication date is 19 March 1992 whereas the present claims are entitled to the benefit of the original filing date in this series of applications, 12 January 1990. However, claims 16-35, for example, in the GenPharm PCT application are directed to transgeneic non-human animals which contain xenogeneic antibody encoding genes. This subject matter overlaps at least to some extent with the subject matter claimed herein.

It is noted that the enclosed GenPharm PCT application claims priority from two U.S. filed applications filed 29 August 1990 and 31 August 1990. These two applications, U.S. 574,748 and U.S. 575,962 and/or any

272

descendants are putatively pending at the U.S. Patent and Trademark Office. The priority date for these applications is approximately eight months subsequent to the priority date claimed herein. Nevertheless, attention of the Office is called to the existence of this series of applications assigned to GenPharm International, Inc. It is assumed that if the Office is aware of the copendency of the GenPharm applications with that herein, the disclosures of the present application can be taken into account in relation to the prosecution of the GenPharm applications with respect to priority of invention.

Consideration of this copending subject matter is respectfully requested.

Respectfully submitted,

By:

Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

MORRISON & FOERSTER
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20007-1888
Tel: (202) 887-1500
Fax: (202) 887-0763
031801.com

273